Founder of Quantimetrix Dies at 89
By LabMedica International staff writers Posted on 24 Oct 2016 |
Image: Quantimetrix founder, Dr. Robert Ban (Photo courtesy of Quantimetrix).
Dr. Robert William Ban, who founded Quantimetrix Corporation (Redondo Beach, CA, USA) over 40 years ago, and led the company's growth into a powerhouse in laboratory liquid control systems, died peacefully in California at the age of 89.
Dr. Ban, a PhD in Bichemistry, started Quantimetrix in 1974 as a result a number of successful experiments he conducted in his garage. The company pioneered a liquid stabilization technology that simplified quality control methods in the laboratory. With the Clinical Laboratory Improvement Act (CLIA) of 1988 mandating the use of controls in clinical laboratories, Quantimetrix provided the products to a diagnostic community eager to abide by the new requirements. The demand for Quantimetrix products soared and established the company as a global leader in the field.
Earlier in 1972, Dr. Ban also founded Diagnostic Products Corporation (DPC), a developer of radioimmunoassay (RIA) diagnostic test kits. The test, considered a breakthrough at the time, permitted the measurement of infinitesimally low concentrations of substances in bodily fluids, such as drugs and hormones. Dr. Ban left DPC in 1973, and subsequently started Quantimetrix.
Dr. Ban was a storied innovator and a tireless leader who was active around the world. His son, Monty Scott Ban, continues to pursue his vision as the current chairman and CEO of the company.
Besides his active business life, Dr. Ban was also a published author, artist, poet, and musician. He is survived by his son, daughter-in-law, and three granddaughters.
Related Links:
Quantimetrix
Dr. Ban, a PhD in Bichemistry, started Quantimetrix in 1974 as a result a number of successful experiments he conducted in his garage. The company pioneered a liquid stabilization technology that simplified quality control methods in the laboratory. With the Clinical Laboratory Improvement Act (CLIA) of 1988 mandating the use of controls in clinical laboratories, Quantimetrix provided the products to a diagnostic community eager to abide by the new requirements. The demand for Quantimetrix products soared and established the company as a global leader in the field.
Earlier in 1972, Dr. Ban also founded Diagnostic Products Corporation (DPC), a developer of radioimmunoassay (RIA) diagnostic test kits. The test, considered a breakthrough at the time, permitted the measurement of infinitesimally low concentrations of substances in bodily fluids, such as drugs and hormones. Dr. Ban left DPC in 1973, and subsequently started Quantimetrix.
Dr. Ban was a storied innovator and a tireless leader who was active around the world. His son, Monty Scott Ban, continues to pursue his vision as the current chairman and CEO of the company.
Besides his active business life, Dr. Ban was also a published author, artist, poet, and musician. He is survived by his son, daughter-in-law, and three granddaughters.
Related Links:
Quantimetrix
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance